SHERWOOD MEDICAL'S FIRST INTRASCOPIC MINIMALLY INVASIVE DEVICES
This article was originally published in The Gray Sheet
Executive SummarySHERWOOD MEDICAL'S FIRST INTRASCOPIC MINIMALLY INVASIVE DEVICES will be introduced at the beginning of the second quarter, the firm says March 1 in announcing its entry into the new line of business. The recently cleared line of laparoscopic irrigation and electrocautery systems was developed by Miami-based Symbiosis, which Sherwood Medical parent American Home Products purchased last September ("The Gray Sheet" Sept. 28, p. 3). The devices will be marketed by the newly developed Sherwood Intrascopic division. Sherwood Medical said in the press release that the Intrascopic division "will be responsible for the company's entry into the rapidly growing minimally invasive surgery market." Robert Egan is vice president and general manager of the new division. The unit, which will operate out of St. Louis where Sherwood is headquartered, currently has approximately 15 employees, including a sales force that exclusively will market Sherwood Intrascopic products. The firm notes that the division is not yet completely staffed. Sherwood Medical says that the development of the new division occurred independently of AHP's acquisition of Symbiosis, which also currently manufactures minimally invasive surgical instruments for Johnson & Johnson's Ethicon Endo-Surgery Division and for Boston Scientific. Sherwood Medical says that Symbiosis will continue to operate as an independent AHP subsidiary, marketing its products through Sherwood Intrascopic as well as other entities. Symbiosis is expected to be one of several sources for Intrascopic division products. Sherwood Medical notes that it continues to pursue "cost effective technologies, both internally and externally, in order to continue developing innovative products" for the Intrascopic division.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.